Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

5.87USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$5.87
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
369,139
52-wk High
$9.18
52-wk Low
$4.45

ZIOP.OQ

Chart for ZIOP.OQ

About

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies... (more)

Overall

Beta: 1.55
Market Cap(Mil.): $777.05
Shares Outstanding(Mil.): 132.38
Dividend: --
Yield (%): --

Financials

  ZIOP.OQ Industry Sector
P/E (TTM): -- 47.82 29.72
EPS (TTM): -1.32 -- --
ROI: -146.19 -2.46 13.00
ROE: -3,423.41 5.18 14.15

BRIEF-Ziopharm Q4 loss per share $0.11

* Ziopharm reports fourth-quarter 2016 financial results and provides update on recent activities

Feb 16 2017

BRIEF-Ziopharm and Intrexon announce cooperative research and development agreement with NCI utilizing sleeping beauty system to generate T Cells targeting Neoantigens

* Ziopharm and Intrexon announce cooperative research and development agreement with the National Cancer Institute utilizing sleeping beauty system to generate T Cells targeting Neoantigens Source text for Eikon: Further company coverage:

Jan 10 2017

BRIEF-Ziopharm announces clinical data on Ad-RTS-hIL-12

* ZIOPHARM oncology - plans to initiate a phase 1 clinical trial in pediatric brain tumors, including diffuse intrinsic pontine glioma (dipg) in 2017

Nov 17 2016

BRIEF-Ziopharm Oncology Q3 loss per share $0.11

* Ziopharm reports third quarter 2016 financial results and provides update on recent activities

Nov 09 2016

BRIEF-Ziopharm reports Q3 loss per share of $0.11

* Ziopharm reports third quarter 2016 financial results and provides update on recent activities

Nov 09 2016

More From Around the Web

Earnings vs. Estimates